Portugal's Permit Backlog Is Squeezing Lesotho's Cannabis Exports

September 28, 2026

Photo by Diego F. Parra via Pexels.

There's a particular kind of shipment that moves through Lisbon customs facilities that most cannabis coverage never mentions: raw, GACP-grade flower grown in southern Africa, trucked or flown into Portugal not to be sold there but to be reprocessed, repackaged, and sent onward into Germany, the UK, and other EU medical markets. Portugal isn't really a destination in this trade. It's a waypoint, a place with the GMP certification infrastructure that lower-cost growing regions like Lesotho haven't built for themselves yet. That quiet middleman role has made Infarmed, Portugal's medicines regulator, one of the more consequential bureaucracies in global medical cannabis without most patients ever hearing its name.

That infrastructure is now under visible strain. A criminal investigation known as Erva Daninha has pushed Infarmed's export permit processing from a fairly predictable 30-day turnaround out to 70 days or more, and the agency has responded to the case by tightening scrutiny across the board -- on paperwork, on the companies involved, on the whole chain of custody -- rather than on any specific batch of medicine. The early evidence of what happens next is already sitting in the trade data: Canadian flower bound for Portugal has been rerouting straight to Germany, skipping the Portuguese processing step entirely. Lesotho, which occupies almost the identical niche in this supply chain, is watching the same pressure build. And because flower is a living, decaying product in a way that oils and capsules simply aren't, a two-month permit delay isn't just an administrative headache. It's time that comes directly out of the product's usable life.

What the Erva Daninha Investigation Actually Charged

Erva Daninha -- Portuguese for weed, in the sense of a nuisance plant, though the name reads as dark irony given the subject matter -- became public in 2025 as a judicial police investigation run out of DCIAP, the Central Department of Investigation and Prosecution, Portugal's unit for organized crime and financial cases. The scope wasn't small. Twenty-four defendants were charged: 13 individuals and 11 companies, spanning what prosecutors describe as a criminal association operating inside the licensed medical cannabis trade, with aggravated charges attached on top of the base offenses. This wasn't street-level diversion. It was activity allegedly running through companies holding legitimate Infarmed licenses, which is precisely why the regulatory fallout has been so broad.

Infarmed's response tells you where the agency thinks the actual exposure lies. Rather than pulling specific medicines or halting particular product lines, the agency tightened scrutiny on traceability records, waste management documentation, and -- most consequentially for exporters -- the vetting of customers and suppliers on both ends of a transaction. That's a slower, more manual review process almost by design, since it requires checking counterparties rather than checking chemistry.

Layered on top of that is a separate requirement that predates the criminal case entirely: since March 2025, a certificate of analysis has been mandatory for every import request. On its own, that rule was a reasonable quality-control step. Combined with the post-Erva Daninha vetting load, it's compounding the current backlog rather than causing it outright -- one more document that has to be correct, current, and cross-checked before a permit clears, at exactly the moment Infarmed's staff are also running deeper background checks on who's shipping and who's receiving. The result is a system doing more verification work per application with no indication staffing has scaled to match it.

From 30 Days to 70-Plus: Measuring the Backlog

Portugal's medical cannabis exports reached 66,305 kg in just the first half of 2026, already amounting to over 83% of the total 79,883 kg exported throughout all of 2025—signaling a sharp acceleration in export volume.

The headline number is straightforward: permits that used to clear in about three weeks are now commonly taking 70-plus days, and cases stretching past two months aren't unusual. For a GACP-grade grower shipping raw flower into Portugal for GMP conversion, that means sitting in a processing queue for months before the finished product ever reaches a buyer in Germany or the UK -- time that didn't exist in this supply chain a year ago.

Vasco Bettencourt, who directs Infarmed's Licensing Unit, addressed the delays directly at the Portugal Medical Cannabis conference in Lisbon on September 10, 2026, and his framing was deliberate: this is a paperwork and partner-vetting problem, he told the room, not a product safety issue. That's a meaningful distinction for anyone downstream trying to gauge risk. A safety-driven slowdown implies the flower itself is being questioned. A vetting-driven slowdown implies the companies and documentation around the flower are being questioned, which is slower to resolve precisely because it depends on background checks and cross-agency confirmation rather than a lab result.

What the delay hasn't done, at least not yet, is collapse volume. Portugal still exported 66,305 kg of medical cannabis in the first half of 2026 alone -- roughly 83% of the 79,883 kg it exported across the entirety of 2025. That's not a market in retreat. It's a market moving slower and reshuffling its winners and losers. Germany absorbed the largest share of that first-half total, taking in 37,442 kg, cementing its position as Portugal's single biggest reported destination even as the permits feeding that pipeline take twice as long to clear.

The throughput numbers, in other words, mask the real story, which is happening at the level of individual shipments and individual growers deciding whether Portugal is still worth the wait.

Canada's Reroute Shows What's at Stake for Lesotho

Photo by Drinu Cutajar via Pexels.

Canada already ran this experiment, and the results are on the record. Canadian flower exports to Portugal have dropped 86.6% from their April 2025 peak -- not because Canadian growers stopped exporting, but because that volume rerouted directly to Germany, bypassing Portugal's GMP processing step altogether. Germany, it turns out, has its own pathways for receiving cannabis that don't strictly require a Portuguese layover, and once the Portuguese leg of the journey started costing extra months, exporters and their buyers simply cut it out.

Lesotho sits in almost the same structural position Canada did. It's a low-cost, GACP-grade grower shipping raw flower into Portugal specifically to access GMP conversion before the product moves on into EU distribution -- the same waypoint arrangement, the same dependency on Portugal's processing capacity rather than its domestic market. That similarity is exactly why the Canadian precedent matters here. If buyers, brokers, and processors start treating Portugal as a bottleneck to be routed around rather than a reliable waypoint, there's no obvious reason Lesotho-origin flower would be exempt from the same calculus. The incentive to find alternative EU entry points, or to push processors in Germany or elsewhere to accept raw GACP flower directly, applies regardless of which continent the flower started on.

What makes this particularly worth watching in Lesotho's case is the relationship's history. Lesotho has spent years building a reputation as one of Africa's earliest and most established medical cannabis exporters, and Portugal has been a central, repeated partner in that story -- one of the main routes by which Lesotho-grown flower has actually reached European patients rather than sitting unsold at home. A relationship built over years of steady processing turnaround is now being tested by a backlog that has nothing to do with Lesotho's growers, its labs, or its compliance record, and everything to do with a criminal case involving Portuguese-licensed companies.

Why Flower Can't Just Wait Out a Backlog

Photo by Elsa Olofsson via Pexels.

Finished cannabis oils and capsules are forgiving. They're stable, shelf-stable by design, and a few extra weeks in a warehouse queue barely registers against their overall stability window. Flower is a different category of product entirely -- it's still biologically active cured plant material, and it keeps degrading from the moment it's harvested regardless of what a permit application says. Terpenes volatilize, cannabinoids slowly convert, and the sensory and therapeutic profile a grower cultivated for shifts whether or not anyone in a regulatory office is paying attention.

Even under Portugal's old, faster 30-day permit timeline, patients weren't exactly getting garden-fresh product. Flower reaching pharmacies has commonly already been around six months old by the time it clears cultivation, curing, transport, processing, and distribution -- that's the normal baseline, not a symptom of the current backlog. A stability date printed at twelve months doesn't mean the product is equally potent or equally fresh on day 40 as it was on day 400; freshness starts sliding well before any formal expiration date arrives, in the same way a bag of good coffee is best within weeks of roasting even though the package might claim a year of shelf life.

That baseline is exactly why adding 40-plus extra days of permit limbo -- time spent after a final certificate of analysis has already been issued, meaning the product itself has already been deemed compliant and is just waiting on paperwork to move -- lands directly on whatever shelf life is left. It's not overlapping with production time. It's stacking on top of it.

For a grower in Lesotho who cured a batch to hit a specific terpene and cannabinoid profile for a specific buyer, that stacking effect is the whole problem. The flower that eventually reaches a pharmacy shelf in Germany or the UK can be meaningfully diminished from what left the farm -- not spoiled or unsafe, just measurably less potent, less aromatic, less representative of what the grower actually produced and what the buyer actually paid for.

Lesotho Is Rebuilding Its Own Permit System in Parallel

Lesotho isn't standing still while Portugal's backlog builds. Legal Notice No. 155 of 2025, the Drugs of Abuse (Cannabis) (Amendment) Regulations, was gazetted on 7 November 2025, and it reworks a meaningful chunk of the country's own export machinery. The amendment refines import-export permit requirements, layers in stricter lab testing obligations, and revises the license and renewal fee structure that growers and exporters operate under.

Procedurally, the change restructures who reviews an application and when. Applications now route first to LeMeRA, the Lesotho Medicines Regulatory Authority, for technical review, before moving on to final vetting by the LNB, the Lesotho National Narcotics Bureau. That's a two-agency sequence where there was previously a simpler path, and while a technical-review-then-security-vetting structure is a defensible model on paper, it's also, structurally, another point where an application can sit and wait.

None of this is finished. Further regulations meant to actually operationalize the underlying Act are still in draft form, with a gazetting target of Q2 of the 2026/7 fiscal year. So Lesotho's regulatory environment is mid-construction, not settled -- growers there are dealing with a framework that's still being built around them at the same time their export destination is dealing with a criminal investigation reshaping how it processes paperwork.

Put those two things side by side and the picture for a Lesotho exporter gets uncomfortable in a specific way: LeMeRA and the LNB are tightening the front door at home, adding review steps and testing obligations before flower even leaves the country, while Infarmed has effectively narrowed the back door in Lisbon, adding vetting steps before that same flower can clear for onward EU distribution. A shipment now has to clear friction on both ends of the same journey, built by two regulators responding to two entirely separate sets of concerns, with no coordination between them that anyone has publicly described.

Strip away the trade data and the permit statistics and Erva Daninha is, at its core, a case about a handful of companies and individuals accused of running a criminal operation inside a licensed system -- 24 defendants, not an industry. But regulatory responses rarely scale down to match the size of the wrongdoing. Infarmed's tightened vetting is landing on every grower who routes flower through Portugal, Lesotho very much included, regardless of whether that grower has ever had a single compliance issue.

The single clearest signal to watch from here isn't anything Infarmed publishes -- it's whether Germany starts absorbing direct GACP shipments from Lesotho the way it already has from Canada. Canada's 86.6% drop from its Portuguese peak wasn't a warning; it was a demonstration. If Lesotho-origin flower starts showing up in German import data without a Portuguese processing stop in between, that's the moment Portugal's role shifts from slowed hub to bypassed one, and that shift, once buyers and processors adjust their routing habits, tends not to reverse just because a backlog eventually clears.

What's notable about Lesotho's position is that its regulators aren't simply waiting to see how that plays out. Rebuilding the permit pathway through LeMeRA and the LNB before international scrutiny forces the issue is a bet that getting ahead of compliance questions matters more, in the long run, than whatever Infarmed decides to do next with its own backlog. Given how little influence a grower in Maseru actually has over a criminal investigation in Lisbon, that's arguably the only lever available -- and it may end up mattering more to Lesotho's export future than anything happening inside Infarmed's offices right now.